drugset / Trial / NCT00269815

Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder

NCT00269815

Phase 3 Completed Alza Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety and effectiveness of OROS® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity disorder (ADHD).

Timeline

Start
Primary completion
Completion
1999-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 18 mg Oral
Subject Methylphenidate Small molecule 36 mg Oral
Subject Methylphenidate Small molecule 54 mg Oral